Lindsey E. Roeker

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak et al. · The Lancet · 2021 · 432 citations · Full text

Phase 1/2, Lymphoid Neoplasia, Medicine +6

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna et al. · Blood · 2020 · 316 citations · Full text

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

Anthony R. Mato, Meghan C. Thompson, John N. Allan et al. · Haematologica · 2018 · 161 citations · Full text

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Skye Montoya, Jessie Bourcier, Mark Noviski et al. · Science · 2024 · 129 citations · Full text

Engineering, Mixed-phenotype Acute Leukemia, Genetics +17

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

Lindsey E. Roeker, David A. Knorr, Melissa S. Pessin et al. · Leukemia · 2020 · 108 citations · Full text

Lymphoid Neoplasia, Immunology, Anti-sars-cov-2 Antibody Response +4